B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

详细信息    查看全文

• 作者：Sara A. J. Thompson ; Joanne L. Jones ; Amanda L. Cox ; D. Alastair S. Compston and Alasdair J. Coles
• 关键词：BAFF ; B ; cell activating factor ; B cells ; autoimmunity ; reconstitution ; T1 B cell ; transitional type I B cell
• 刊名：Journal of Clinical Immunology
• 出版年：2010
• 出版时间：January, 2010
• 年：2010
• 卷：30
• 期：1
• 页码：99-105
• 全文大小：171.5 KB

文摘

Introduction Treatment with alemtuzumab is highly effective in relapsing–remitting multiple sclerosis; however, 30 % of patients develop autoimmunity. Alemtuzumab (previously called Campath 1-H) induces a prolonged T-cell lymphopenia with memory cells dominating the reconstituting T-cell pool for at least 3 months.